Kiek dividendų moka Hangzhou Tigermed Consulting Co 2025?
Pagal paskutinę informaciją nuo rugpjūtis 2025, Hangzhou Tigermed Consulting Co per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,57 CNY už akciją. Esant dabartiniam Hangzhou Tigermed Consulting Co kursui 66,28 CNY, tai atitinka 0,86 % dividendų grąžą.
Dividendai mokami kartus per metus.
0,86 % Dividendo grąža | = | 0,57 CNY Dividendas | 66,28 CNY akcijų kaina |
|
Ar Hangzhou Tigermed Consulting Co dividendai yra saugūs?
Hangzhou Tigermed Consulting Co kasmet didina dividendus jau 6 metus.
Per pastaruosius 10 metus Hangzhou Tigermed Consulting Co kasmet 23,886 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 19,474 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų mažinimas bus −24,298%.
Hangzhou Tigermed Consulting Co Aktienanalyse
Ką daro Hangzhou Tigermed Consulting Co?
Hangzhou Tigermed Consulting Co Ltd is a leading Chinese company in the field of clinical research and medical services. The company was founded in Hangzhou in 2004 and has since experienced rapid development. Today, the company has branches in over 20 countries and employs over 11,000 people worldwide.
Hangzhou Tigermed's business model is based on supporting the entire value chain of clinical trials, from planning and execution to statistical analysis and data interpretation. The company works closely with global actors from the pharmaceutical industry, biomedical research institutions, and regulatory authorities to meet international standards for clinical studies.
Over the years, Hangzhou Tigermed has expanded its business activities to include various areas such as data management, biostatistics, medical translation, clinical monitoring, drug safety monitoring, and traceability.
An important part of Hangzhou Tigermed's business model is the ability to use high-tech platforms and IT systems to enable real-time monitoring and communication during a clinical trial. This allows the company to quickly respond to adverse events and monitor the progress of the study in real-time.
The company also offers specialized services, such as the evaluation of oncology studies and the conduct of studies in the field of traditional Chinese medicine. In addition, Hangzhou Tigermed also has its own pharmaceutical research department specializing in the development of innovative drugs.
The company has built strong research and development capabilities, with a focus on open innovation projects and partnerships with research institutions and pharmaceutical companies. In collaboration with its industry partners, Hangzhou Tigermed has conducted a number of research projects that have led to significant innovations in medicine.
Hangzhou Tigermed also has a strong presence in the international market, particularly in North America and Europe. Through its branches in these regions, the company is able to offer comprehensive collaboration to its customers on a global level.
Overall, Hangzhou Tigermed Consulting Co Ltd has established itself as a significant force in the clinical research industry. The company has developed a wide range of services to meet the needs of its customers in the industry. Hangzhou Tigermed's ability to work closely with its customers and adhere to global standards has helped it become a preferred partner for clinical studies and innovative research projects worldwide. Hangzhou Tigermed Consulting Co yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.